Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on September 29, 2025.
• Khattar acquired 13,688 shares of common stock by exercising employee stock options at a price of $25.30 per share.
• Concurrently, he disposed of 10,235 shares of common stock at a weighted average price of $48.02 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Khattar directly beneficially owns 1,144,336 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust, totaling 2,149,936 shares.
• He also holds 148,812 unexercised employee stock options.

Sentiment

Score: 6

Explanation: The exercise of options at a lower price and subsequent sale at a higher price indicates a profitable transaction for the executive. The use of a 10b5-1 plan suggests a pre-planned, non-discretionary sale, which is generally viewed more favorably than opportunistic selling. The executive also retains a significant stake in the company.

Positives

• The exercise of options indicates the executive is realizing value from previously granted equity compensation.
• The exercise price of $25.30 is significantly lower than the sale price of $48.02, indicating a substantial personal gain for the CEO.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned, non-discretionary sale, mitigating concerns about opportunistic insider selling.
• Khattar retains a substantial direct and indirect beneficial ownership of 2,149,936 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The disposition (sale) of 10,235 shares by a key executive, even under a 10b5-1 plan, could be perceived negatively by some investors as it reduces direct ownership.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing, which solely reports insider transactions.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management, as it is a transactional report.

Industry Context

This filing reports routine insider transactions under a pre-arranged plan and does not provide specific information to analyze broader industry trends or competitive positioning for Supernus Pharmaceuticals. Such transactions are common across industries for executives managing their equity compensation.

Comparison to Industry Standards

• Insider transactions, particularly those executed under Rule 10b5-1 plans, are a standard practice for executives in publicly traded companies across various industries to manage their personal finances and diversify holdings while complying with insider trading regulations.
• The reported transactions are consistent with typical executive equity compensation management strategies.
• No specific comparable companies or projects are mentioned in this transactional filing.

Corporate Governance

Legal Proceedings

• This filing does not mention any litigation or regulatory matters.

Related Party Transactions

• The filing notes indirect beneficial ownership of 1,005,600 shares by the KBT Trust, which is a standard disclosure for beneficial ownership and not a new related party transaction.

Stakeholder Impact

• Shareholders: May view the sale of shares by the CEO with mixed sentiment; while it's a planned transaction, some may interpret it as a reduction in direct exposure. However, the significant retained ownership and the 10b5-1 plan mitigate negative perceptions.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

While the CEO's sale of shares might raise some questions, it was conducted under a pre-arranged 10b5-1 plan, which is a common and compliant method for executives to manage their equity compensation. The CEO also retains a substantial direct and indirect ownership stake, indicating continued alignment with the company's performance. This Form 4 primarily reports a routine insider transaction and does not provide new fundamental information about the company's operations or future prospects that would warrant a change from a 'hold' position based solely on this filing.

Keywords

Supernus Pharmaceuticals, SUPN, Jack Khattar, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Beneficial Ownership, CEO, Director